Although ICB therapies, particularly PD-1/PD-L1 blockade, are being actively tested in a number of hematological malignancies, it remains to be fully understood why blockade of PD-1/PD-L1 shows efficacy in only limited tumor types. This evidence concerns the gene PDCD1 and neoplasm.